Echelon Biosciences
Echelon Biosciences公司 Echelon Biosciences代理 Echelon Biosciences中国代理 Echelon Biosciences授权签约代理
About Echelon Biosciences
About Us
Scientific Focus
Management
About Frontier Scientific Inc.
Echelon Biosciences Incorporated (EBI) was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. Initially, EBI was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, with the aim to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.
From 1997 through 2004, EBI primarily used government grants and product sales revenues to fund its research efforts. In early 2005, EBI was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP anti-infectives, PI3-Kinase small molecule program, catalog business, and scientific expertise. In late 2007, Frontier Scientific Incorporated (FSI) based in Logan, Utah purchased EBI. Specializing in porphyrin and boron chemistry, FSI opened the doors for expanded research.
Since 1997, EBI has retained its commitment to developing novel assays and reagents for lipid research and beyond. At EBI’s core is the desire to innovate, thus pushing medicinal research to new limits. We look forward to providing scientists around the world with the tools they need to cure human disease states for years to come and we welcome any suggestions about how we can better do so.
Thank you for visiting echelon-inc.com.
Scientific Focus
Cancer
Liver Disease
Allergies
Type II Diabetes
Anti-Infectives
Management
W. Tim Miller, MBA, President and CEO
Mr. Miller is an experienced CEO, has been with Echelon 5 years and has 30 years of practice building successful teams in public and private companies. Recent successes include the building and strategic exit of a bio-pharma company and an IPO for a trans-dermal drug delivery company. With a successful history in strategic planning, operations, business development, and funding, his drug/device experience includes Marion Laboratories, American Home Products Corporation, American Hospital Supply Corporation, William H. Rorer, and Iomed, Inc. His M.B.A. is from the University of Utah where he graduated first in his class with honors. For two consecutive years, he has been recognized as one of Utah?s top 100 venture entrepreneurs and is an Adjunct Professor of Business at the University of Utah. He helped establish Angel Flight (www.angelflight.org) in Utah in 1999.
Charles (Chad) Testa, Ph.D., Vice President of Research & Development
Dr. Charles Testa has spent the previous 10 years studying isoprenoid biosynthesis, with the majority being focused on the MEP pathway. He has a B.A. in Biochemistry from Ithaca College, an M.S. from Bucknell University and a Ph.D. in Chemistry from the University of Utah. Dr. Testa has been at Echelon for 5 years where he has progressed from Research Scientist to Project Manager to Director of Anti-infective Drug Development.
Paul Neilsen, Ph.D., Director of Research & Development
Dr. Neilsen has a BS in biochemistry from Brigham Young University and a Ph.D. with honors in Experimental Pathology from the University of Utah. Primary or contributing author for 8-10 peer-reviewed scientific papers including Journal of Biological Chemistry, Nature Cell Biology, and Journal of Immunology. He is an Adjunct Professor of Biology at Salt Lake Community College.
Colin G. Ferguson, Ph.D., Director of Applied Tech
Dr. Ferguson has a B.S. with honors in Chemistry and Oceanography, University of British Columbia, Vancouver; a Ph.D. in Chemistry, Queens University, Kingston, Ontario, Canada; and a Postdoctoral Fellow, Medicinal Chemistry, University of Utah. His knowledge of phosphoinositide syntheses allows Echelon to expand its product offerings and constantly improve its operational efficiencies.
Kelly Sauder, Accounting and Human Resources Manager
Kelly Sauder is the accounting manager of Echelon Biosciences, Inc, with responsibilities in both accounting and human resources. She has BS degrees in Accounting and Business Economics. She has 5 years experience in public accounting and auditing, 2 years experience in the private business sector, and is currently pursuing CPA certification.
Nathan Rupert, MBA, Director of Marketing
Nathan Rupert offers over nine years of direct sales and marketing experience to EBI. His technical know-how has since been complimented with an MBA from the University of Utah's David Eccles School of Business with emphases in marketing and product management. Mr. Rupert is charged with Echelon's advertising, product management, and market research responsibilities.
About Frontier Scientific Inc.
Frontier Scientific, Inc. (FSI) was founded in 1975 by Dr. Bruce Burnham under the name Porphyrin Products, Inc.
Dr. Burnham perceived a need for Porphyrin and related compounds and soon found that as he made the compounds available that new research was spawned. A listing of standard compounds soon generated requests for custom compounds and projects.
In 1977 Dr. Jerry Bommer joined Porphyrin Products and was integral in developing key products that have been vital to the success of the company.
An outside party contracted Porphyrin Products in the mid 1980’s to develop a Photo Dynamic Therapy (PDT) drug. This project culminated in a GMP production of an inject-able PDT drug for Phase I clinical trials. Due to economic conditions in the early 1990’s the project was taken to another country to continue the Phase II and Phase III clinical trials.
Due to health conditions Dr. Burnham decided to sell the company. In 1995 a new group of shareholders purchased the company.
Since 1995 FSI has developed molecules for insecticide and antimicrobial use that has been tested against gram positive and gram negative targets using light as an activation source. Also, a potential drug to treat Hemochromatosis has been developed and tested in rats and initial results show efficacy. A patent has been issued for the first project and a patent is pending on the second project. Several other projects are in process and add to FSI’s intellectual property treasure chest.
In 1997 Porphyrin Products started a new line of chemistry focused on combinatorial chemistry and cross coupling technology. FSI was the first company to provide Bis(pinacolato) diboron on a commercial basis. To accommodate the company moving into additional areas of chemistry the company name was changed to Frontier Scientific, Inc. in 1999. The name Porphyrin Products is still used to market the Porphyrin compounds. In addition the company continues to provide new and novel compounds many of which are only available from FSI.
Since the inception of the company custom synthesis has been a large component of the business and this continues to be the case. In 1998 FSI was contracted by a major industrial chemical company for manufacture of custom compounds. FSI manufactured up to 100 kg of specific compounds with purity requirements of > 99.5%. Frontier’s reputation for high purity and on time delivery has been built with experience.
In 2002 FSI established our R&D department to focus on new generation compounds and custom synthesis needs of our customers. This group of highly skilled scientist has synthesized hundreds of new compounds for a variety of companies and applications from milligram to multi-kilo scale while meeting the specifications of the customer.
In 2004 FSI produced an intermediate compound for a pharmaceutical company that was used in Phase I and Phase II clinical trials. This project started in the gram quantity and grew to greater than 50 Kg. Again the purity was an essential element to the customer as well as timely delivery.
In 2005 FSI engaged in Contract Research Organization (CRO) agreements to provide contract research for various companies. Also, our R&D group has been very active in providing our customers with unique compounds which in most cases are not available on a commercial basis from anyone else in the world.
FSI remains committed to developing novel organic compounds for drug discovery. Every day, FSI chemists are researching and developing new products for medicinal chemists around the world and look forward to the opportunity the future brings to serve you and your chemistry needs.
